Candel Therapeutics Stock Performance
| CADL Stock | USD 8.06 0.19 2.30% |
Candel Therapeutics has a performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of -0.31, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Candel Therapeutics are expected to decrease at a much lower rate. During the bear market, Candel Therapeutics is likely to outperform the market. Candel Therapeutics right now shows a risk of 6.25%. Please confirm Candel Therapeutics downside variance, rate of daily change, and the relationship between the maximum drawdown and skewness , to decide if Candel Therapeutics will be following its price patterns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Candel Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite quite persistent fundamental indicators, Candel Therapeutics is not utilizing all of its potentials. The latest stock price mess, may contribute to short-term losses for the institutional investors. ...more
Actual Historical Performance (%)
One Day Return (2.30) | Five Day Return 1.26 | Year To Date Return (10.34) | Ten Year Return 15.14 | All Time Return 15.14 |
1 | Disposition of 50000 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 8.52 subject to Rule 16b-3 | 12/23/2024 |
2 | Disposition of 50000 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 8.82 subject to Rule 16b-3 | 12/24/2024 |
3 | Disposition of 50000 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 9.01 subject to Rule 16b-3 | 12/26/2024 |
4 | Disposition of 50000 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 8.85 subject to Rule 16b-3 | 12/27/2024 |
5 | Disposition of 9884 shares by Charles Schoch of Candel Therapeutics at 6.4726 subject to Rule 16b-3 | 01/03/2025 |
6 | Acquisition by Nguyen Diem of 14240 shares of Candel Therapeutics at 5.71 subject to Rule 16b-3 | 01/07/2025 |
7 | Disposition of 10428 shares by Nichols William Garrett of Candel Therapeutics at 7.225 subject to Rule 16b-3 | 01/15/2025 |
8 | FMR LLCs Strategic Acquisition of Candel Therapeutics Shares | 02/07/2025 |
9 | Disposition of 31335 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 8.61 subject to Rule 16b-3 | 02/10/2025 |
10 | Acquisition by Barone Francesca of 115000 shares of Candel Therapeutics at 8.55 subject to Rule 16b-3 | 02/12/2025 |
11 | This GE Vernova Analyst Begins Coverage On A Bullish Note Here Are Top 5 Initiations For Wednesday | 02/19/2025 |
12 | Disposition of 10582 shares by Aguilar-cordova Estuardo of Candel Therapeutics at 12.02 subject to Rule 16b-3 | 02/21/2025 |
13 | Insiders Enjoy US1.3m Return After Buying Candel Therapeutics Stock | 02/28/2025 |
14 | Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights | 03/13/2025 |
15 | Disposition of 5000 shares by Charles Schoch of Candel Therapeutics at 8.8338 subject to Rule 16b-3 | 03/17/2025 |
16 | Disposition of 25772 shares by Tak Paul Peter of Candel Therapeutics at 8.7701 subject to Rule 16b-3 | 03/18/2025 |
17 | Disposition of 400 shares by Tak Paul Peter of Candel Therapeutics at 9.0025 subject to Rule 16b-3 | 03/19/2025 |
| Begin Period Cash Flow | 35.7 M |
Candel |
Candel Therapeutics Relative Risk vs. Return Landscape
If you would invest 863.00 in Candel Therapeutics on December 22, 2024 and sell it today you would lose (57.00) from holding Candel Therapeutics or give up 6.6% of portfolio value over 90 days. Candel Therapeutics is currently generating 0.0876% in daily expected returns and assumes 6.2501% risk (volatility on return distribution) over the 90 days horizon. In different words, 55% of stocks are less volatile than Candel, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Candel Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Candel Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Candel Therapeutics, and traders can use it to determine the average amount a Candel Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.014
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | CADL | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.25 actual daily | 55 55% of assets are less volatile |
Expected Return
| 0.09 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 1 99% of assets perform better |
Based on monthly moving average Candel Therapeutics is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Candel Therapeutics by adding it to a well-diversified portfolio.
Candel Therapeutics Fundamentals Growth
Candel Stock prices reflect investors' perceptions of the future prospects and financial health of Candel Therapeutics, and Candel Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Candel Stock performance.
| Return On Equity | -4.81 | ||||
| Return On Asset | -0.52 | ||||
| Current Valuation | 300.51 M | ||||
| Shares Outstanding | 32.48 M | ||||
| Price To Book | 5.88 X | ||||
| Price To Sales | 436.42 X | ||||
| Gross Profit | (20.66 M) | ||||
| EBITDA | (33.37 M) | ||||
| Net Income | (55.18 M) | ||||
| Cash And Equivalents | 86.78 M | ||||
| Cash Per Share | 3.00 X | ||||
| Total Debt | 10.87 M | ||||
| Debt To Equity | 0.38 % | ||||
| Current Ratio | 14.86 X | ||||
| Book Value Per Share | 0.44 X | ||||
| Cash Flow From Operations | (27.02 M) | ||||
| Earnings Per Share | (1.73) X | ||||
| Market Capitalization | 134.29 M | ||||
| Total Asset | 106.87 M | ||||
| Retained Earnings | (192.21 M) | ||||
| Working Capital | 66.28 M | ||||
About Candel Therapeutics Performance
By examining Candel Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Candel Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Candel Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.06) | (1.01) | |
| Return On Capital Employed | (0.48) | (0.51) | |
| Return On Assets | (1.06) | (1.01) | |
| Return On Equity | (3.42) | (3.25) |
Things to note about Candel Therapeutics performance evaluation
Checking the ongoing alerts about Candel Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Candel Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Candel Therapeutics had very high historical volatility over the last 90 days | |
| Net Loss for the year was (55.18 M) with loss before overhead, payroll, taxes, and interest of (20.66 M). | |
| Candel Therapeutics currently holds about 86.78 M in cash with (27.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.0. | |
| Candel Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 30.0% of the company shares are held by company insiders | |
| Latest headline from gurufocus.com: Disposition of 25772 shares by Tak Paul Peter of Candel Therapeutics at 8.7701 subject to Rule 16b-3 |
- Analyzing Candel Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Candel Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Candel Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Candel Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Candel Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Candel Therapeutics' stock. These opinions can provide insight into Candel Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Candel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Candel Therapeutics. If investors know Candel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Candel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Candel Therapeutics is measured differently than its book value, which is the value of Candel that is recorded on the company's balance sheet. Investors also form their own opinion of Candel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Candel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Candel Therapeutics' market value can be influenced by many factors that don't directly affect Candel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Candel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Candel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Candel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.